EA201690926A1 - Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек - Google Patents

Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Info

Publication number
EA201690926A1
EA201690926A1 EA201690926A EA201690926A EA201690926A1 EA 201690926 A1 EA201690926 A1 EA 201690926A1 EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A1 EA201690926 A1 EA 201690926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
increase
patients
iii
reduce
Prior art date
Application number
EA201690926A
Other languages
English (en)
Russian (ru)
Inventor
Энрике Порадосу
Рон Бентсур
Джеймс Ф. Оливьеро III
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201690926A1 publication Critical patent/EA201690926A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201690926A 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек EA201690926A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
EA201690926A1 true EA201690926A1 (ru) 2016-09-30

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690926A EA201690926A1 (ru) 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Country Status (15)

Country Link
US (3) US20160256486A1 (cg-RX-API-DMAC10.html)
EP (2) EP3065734A4 (cg-RX-API-DMAC10.html)
JP (3) JP2016535780A (cg-RX-API-DMAC10.html)
KR (1) KR102392441B1 (cg-RX-API-DMAC10.html)
CN (1) CN105873583A (cg-RX-API-DMAC10.html)
AU (1) AU2014341975A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016009901A8 (cg-RX-API-DMAC10.html)
CA (1) CA2928200A1 (cg-RX-API-DMAC10.html)
EA (1) EA201690926A1 (cg-RX-API-DMAC10.html)
HK (1) HK1223031A1 (cg-RX-API-DMAC10.html)
IL (1) IL245317A0 (cg-RX-API-DMAC10.html)
MX (1) MX2016005734A (cg-RX-API-DMAC10.html)
SG (1) SG11201603091QA (cg-RX-API-DMAC10.html)
TW (2) TWI744215B (cg-RX-API-DMAC10.html)
WO (1) WO2015066593A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (cg-RX-API-DMAC10.html) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
EP1978808B1 (en) 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
WO2015066593A1 (en) 2015-05-07
KR102392441B1 (ko) 2022-05-02
JP2019206562A (ja) 2019-12-05
MX2016005734A (es) 2016-11-08
US20250360167A1 (en) 2025-11-27
EP3747432A1 (en) 2020-12-09
JP2021073230A (ja) 2021-05-13
SG11201603091QA (en) 2016-05-30
TW201609088A (zh) 2016-03-16
EP3065734A4 (en) 2017-05-17
KR20160096597A (ko) 2016-08-16
US20160256486A1 (en) 2016-09-08
CA2928200A1 (en) 2015-05-07
BR112016009901A8 (pt) 2020-04-14
AU2014341975A1 (en) 2016-05-19
TW202203910A (zh) 2022-02-01
US20190307791A1 (en) 2019-10-10
HK1223031A1 (zh) 2017-07-21
JP2016535780A (ja) 2016-11-17
CN105873583A (zh) 2016-08-17
IL245317A0 (en) 2016-06-30
JP6828100B2 (ja) 2021-02-10
TWI744215B (zh) 2021-11-01
EP3065734A1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
MX2016005734A (es) Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MY178542A (en) Blood brain barrier shuttle
EA201591762A1 (ru) Человеческие антитела к grem1
PH12015502275B1 (en) Therapuetic uses of empagliflozin
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
Chavez et al. New insights into the regulation of vascular permeability
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
PH12015502301A1 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
EA201891533A1 (ru) Способы и композиции для лечения синдрома хантера
BR112014032781A2 (pt) dispositivo para aumentar fluxo sanguíneo, perfusão tecidual e distribuição de fluidos por estimulação neuromuscular em cavalos e outros mamíferos não-humanos
EA202090028A1 (ru) Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
UA86387U (ru) Способ оценки эффективности лечения больных с артериальной гипертензией, объединенной с метаболическим синдромом
Chairkin et al. CHANGE IN THE STRUCTURE OF THE ADRENAL CORTEX ON THE FIRST DAY AFTER ACUTE BLOOD LOSS
UA107451U (uk) Спосіб комплексної оцінки резистентності еритроцитів у хворих на хронічну хворобу нирок vд стадії з анемією, які лікуються нирковозамісною терапією різної модальності
RU2015112811A (ru) Способ лечения больных с обострением хронического бескаменного холецистита
UA87683U (uk) Спосіб діагностики діастолічної дисфункції лівого шлуночка серця у хворих на гіпертонічну хворобу